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Background
Dacarbazine (DTIC) is currently the only agent approved
throughout Europe for patients with previously untreated,
advanced melanoma that is not restricted by tumour geno-
type (e.g. BRAF status). Based on recent trials in patients
with previously untreated, advanced melanoma, median
overall survival (OS) and a 1-year OS rate of approxi-
mately 9 months and 36% represent conservative, histori-
cal benchmarks for DTIC monotherapy [1–5]. Data from
clinical trials and expanded access programmes show that
ipilimumab treatment consistently provides a proportion
of patients with long-term clinical benefit, irrespective of
whether they are pretreated or treatment-naive. In Europe,
ipilimumab is indicated for use in adult patients who have
received prior therapy. To support the use of ipilimumab
in the previously untreated setting, data were analysed
from ipilimumab clinical trials.
Materials and methods
Data were pooled from chemotherapy-naive patients
who received ipilimumab 3 mg/kg as monotherapy in
one of four randomised clinical trials: MDX010-20
(NCT00094653), a phase 3 trial of ipilimumab alone or in
combination with gp100 vaccine versus the vaccine alone;
MDX010-08 (NCT00050102), a phase 2 multi-dose study
of ipilimumab with or without dacarbazine; CA184-004
(NCT00261365), a prospective phase 2 biomarker study,
and CA184-022 (NCT00289640), a phase 2, dose-ranging
study. Details on these four trials have previously been
published [6–9]. Patients received ipilimumab 3 mg/kg x 4
doses with the option for retreatment (MDX010-20) or
maintenance therapy (CA184-004/022).
Results
Of the patients who received ipilimumab 3 mg/kg within
one of the four clinical trials described above, 78 had not
received prior chemotherapy and were eligible for analysis.
Of these, 27% had elevated lactate dehydrogenase levels at
baseline and 53% had received prior immunotherapy
for advanced melanoma. With a median follow-up of
11.6 months (range: 0.03–69.7), median overall survival
was 13.47 months (95% confidence intervals [CI]: 11.2–
19.6) and the one- and two-year survival rates were 54.1%
(95% CI: 42.5–65.6) and 31.6% (95% CI: 20.7–42.9),
respectively. Survival outcomes compared favourably to
historical observations with dacarbazine in phase 3 trials
of patients with previously untreated, advanced melanoma.
Conclusions
Therapeutic options for treatment-naïve patients remain
limited. OS data from chemotherapy-naive patients.
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